Clinical Genomics is vying for a space in the saturated liquid biopsy market, and now it has some funds to help it along the way. The company reeled in $15 million in a Series A round to support development of its genetic test for colorectal cancer.
Sydney, Australia-based VC firm OneVentures led the round.
Posted in — Fierce Biotech
